Figure 3. TC-1 and LLC tumor-bearing mice show evidence of systemic inflammation but only TC-1 has increased hepcidin mRNA.

By day 14, (A) both tumor models have increased levels of liver SAA-1 mRNA; (B) TC-1-bearing mice have increased liver hepcidin mRNA levels compared to controls, and LLC-bearing mice have decreased hepcidin. N = 8–19 mice per treatment and control group. *P<0.05; P by Mann-Whitney rank sum test. Bars and error bars are median ±75^th/25^th percentile.